SCHEMBL682767

SCHEMBL682767

CC(C)c1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
C5AR1 P21730 1/20 0.47
CCR5 P51681 1/20 0.47
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 1/20 0.46
GLRA1 P23415 1/20 0.46
LIPE Q05469 1/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
F2 P00734 1/20 0.45
F10 P00742 1/20 0.45
PRSS1 P07477 1/20 0.45
PRSS2 P07478 1/20 0.45
F7 P08709 1/20 0.45
F3 P13726 1/20 0.45
PRSS3 P35030 1/20 0.45
KMT2A Q03164 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17833745 0.92 SMPD1 (0.53) MAPK1RAB9AALDH1A1KDM4ELMNA
SCHEMBL12738664 0.92 NPC1 (0.55) MAPTRAB9AALDH1A1KDM4EF2
SCHEMBL28815272 0.88 CCR5 (0.49) MAPTMAPK1TDP1L3MBTL1C5AR1
SCHEMBL30280437 0.87 HPGD (0.49) MAPTMAPK1TDP1L3MBTL1C5AR1
SCHEMBL8886459 0.87 MAPT (0.46) MAPTMAPK1TDP1L3MBTL1C5AR1
SCHEMBL12889910 0.87 GLRA1 (0.50) MAPTMAPK1TDP1L3MBTL1CCR5
SCHEMBL14200042 0.87 KEAP1 (0.53) MAPTMAPK1TDP1L3MBTL1ALDH1A1
SCHEMBL8886562 0.87 HPGD (0.49) MAPTMAPK1TDP1L3MBTL1C5AR1
SCHEMBL12868786 0.87 FFAR4 (0.54) MAPTMAPK1TDP1L3MBTL1CCR5
SCHEMBL10710291 0.87 CFD (0.49) MAPTMAPK1TDP1L3MBTL1C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022270478-A1 ANTIVIRAL AGENT 国立大学法人北海道大学 2022-12-29 WO disclosed
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF MAPT 1368/4885MAPK1 470/4885TDP1 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.